Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Pfizer’s Chinese drug acquisition ... Expect a mob of Wall Street analysts and investors. AstraZeneca’s plenary streak continues: This is the seventh consecutive year that AstraZeneca has ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a bispecific antibody newly licensed by Pfizer.

The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

David Fredrickson, executive vice president of AstraZeneca's oncology business ... therapy than if you wait till a second one." Pfizer impresses in colorectal cancer – The company's pill ...

AstraZeneca wins big (again ... from a more effective frontline therapy than if you wait till a second one." Pfizer impresses in colorectal cancer – The company's pill Braftovi, combined ...

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% ...

S hares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S.